1 atients had adverse events in the extension (aphthous ulcer).

2  thalidomide may promote the healing of oral aphthous ulcers.

3 candidiasis, and topical corticosteroids for aphthous ulcers.

4 ver time, but no change in the occurrence of aphthous ulcers.

5 11%] patients), headache (19 [9%] patients), aphthous ulcer (15 [7%] patients), and nausea (13 [6%] p

6  300 mg and 150 mg doses, respectively), and aphthous ulcers (38 [4%] of 870 and six [3%] of 214, res

7 p (55 percent) had complete healing of their aphthous ulcers after four weeks, as compared with only

8 peutic presently used in the clinic to treat aphthous ulcers and asthma, is an inhibitor of these kin

9                    Saliva from patients with aphthous ulcers and Behcet disease prone to oral ulcers

10 o of the more common oral mucosal disorders: aphthous ulcers and recurrent herpes simplex labialis.

11 virus (HIV)-associated conditions, including aphthous ulcers and wasting syndrome.

12   Dry mouth, oral candidiasis, and recurrent aphthous ulcers are 3 of the most common oral conditions

13   Dry mouth, oral candidiasis, and recurrent aphthous ulcers are common oral conditions that may be a

14  study: hepatic enzyme increased, dizziness, aphthous ulcer, arthralgia, arthritis, increased appetit

15  receive thalidomide had complete healing of aphthous ulcers at the 4-week endoscopic evaluation, com

16       In general, peripheral arthritis, oral aphthous ulcers, episcleritis, or erythema nodosum can b

17 led study of thalidomide as therapy for oral aphthous ulcers in HIV-infected patients.

18 s is ineffective at preventing recurrence of aphthous ulcers in HIV-infected persons.

19 reventing recurrences of oral and esophageal aphthous ulcers in patients with human immunodeficiency

20               The hypothesis tested was that aphthous ulcers may lack key extracellular matrix compon

21 not in pseudohairy leukoplakia lesions, oral aphthous ulcers, or oral KS lesions.